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Abstract: Mutations in PINK1, which impair its catalytic kinase activity, 
are causal for autosomal recessive early onset Parkinson’s disease 
(PD). Various studies have indicated that the activation of PINK1 
could be a useful strategy in treating neurodegenerative diseases 
such as PD. Herein, we show that the anthelmintic drug niclosamide 
and its analogues are capable of activating PINK1 in cells via 
reversible impairment of the mitochondrial membrane potential. Using 
these compounds, we demonstrate for the first time that the PINK1 
pathway is active and detectable in primary neurons. Our findings 
suggest that niclosamide and its analogues are robust compounds to 
study the PINK1 pathway and may hold promise as a therapeutic 
strategy in Parkinson’s and related disorders.  
Loss-of-function mutations in the genes encoding the PTEN 
(phosphatase and tensin homologue deleted on chromosome 
10)-induced kinase 1 (PINK1) and the E3 ubiquitin ligase Parkin 
lead to autosomal recessive early-onset PD.
[1]
 PINK1 is a 
serine/threonine protein kinase that possesses an N-terminal 
mitochondrial targeting sequence, a transmembrane domain, and 
three insertional loops within its catalytic kinase domain.
[2]
 A large 
body of cell biological and biochemical analyses has linked PINK1 
to the regulation of mitochondrial homoeostasis.
[3]
 Indeed, it is 
now understood that upon mitochondrial membrane 
depolarization, PINK1 becomes activated and consequently 
phosphorylates Parkin and ubiquitin at a conserved serine 65 
(Ser65) residue. This stimulates Parkin recruitment to the 
mitochondria whereupon it becomes maximally active and 
ubiquitylates multiple substrates on the outer mitochondrial 
membrane to trigger degradation of damaged mitochondria via 
autophagy (mitophagy).
[4]
  
The majority of PD-related PINK1 mutations abrogate its kinase 
activity
[5]
 and prevent the initiation of mitophagy in cells upon 
mitochondrial damage leading to the accumulation of reactive 
oxygen species and premature neuronal loss.
[6]
 This underlines 
the kinase activity of PINK1 as being critical to the prevention of 
neurodegeneration. Such hypothesis has been verified in 
Drosophila models of PINK1 in which kinase-inactive versions of 
PINK1 failed to rescue neurodegeneration compared to the wild-
type gene.
[7]
 This important finding highlighted the activation of 
PINK1 as a promising strategy for inducing and maintaining 
neuroprotective effects. 
To date, a series of agents have been reported to efficiently 
activate PINK1 in various immortalized human cell lines. These 
could be divided into two groups; compounds that act directly as 
PINK1 ATP neosubstrates
[8]
 and indirect PINK1 activators that 
cause the loss of the mitochondrial membrane potential (∆ym)
[9]
. 
Undoubtedly, the latter class of compounds, which include the 
proton ionophore, carbonyl cyanide m-chlorophenyl hydrazone 
(CCCP), the potassium uniporter valinomycin, or a combination of 
Antimycin A and Oligomycin A (O/A) have attracted more interest 
in the study of PINK1-signalling. Despite the promise of these 
agents in activating PINK1, their cellular toxicity has limited their 
translation to activating PINK1 in vivo. Hence, the elaboration of 
novel and safe (direct or indirect) activators of PINK1 is of great 
biological and therapeutic interest.  
As indirect PINK1 activation can be triggered by the uncoupling of 
the mitochondria,
[9]
 we focused our search of small molecule 
PINK1 activators on niclosamide (Figure 1A), an anthelminthic 
drug that was previously reported for its potential in treating 
myeloma through the uncoupling of oxidative phosphorylation in 
the mitochondria.
[10]
 Given that niclosamide has been used for a 
long time as a safe anthelminthic drug
[11]
 and studied in vivo with 
no apparent severe side effects,
[12]
 we were encouraged to 
explore the activation of PINK1 by this clinical agent. For this, 
untagged Parkin was expressed in both wild-type and PINK1 
knockout HeLa cells generated by CRISPR/Cas9 technology.
[13]
 
The cells were treated with different concentrations of 
niclosamide (0.2-20 µM) for 40 min, DMSO or 10 µM Antimycin A 
/1 µM Oligomycin (A/O) for 3 h. The cell lysates were 
immunoblotted with an anti-phospho-Parkin Ser65 antibody to 
monitor PINK1 activity.
[4c]
 Niclosamide has been shown to 
uncouple the mitochondria preventing the creation of adenosine 
triphosphate (ATP).
[12b]
 To monitor for the ability of niclosamide 
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and A/O to induce mitochondrial uncoupling, we probed for the 
cleavage of the mitochondrial protein, optic atrophy protein 1 
(OPA1), that is catalyzed by the zinc metalloprotease, OMA 1, 
upon mitochondrial membrane depolarization in cells.
[14]
 We 
observed mild activation of PINK1 as judged by Parkin Ser65 
phosphorylation at 0.2 μM and more striking activation at 2 μM or 
higher concentrations of niclosamide comparable to that induced 
by A/O treatment at 3 h (Figures 1B). This was associated with 
ubiquitylation of the mitochondrial Fe/S domain containing protein, 
CISD1, that is a readout of Parkin ubiquitin E3 ligase activity 
(Figure 1B).
[15]
  
 
Figure 1. Niclosamide activates PINK1 in HeLa cells. A. Chemical structure 
of niclosamide. B. Niclosamide dose-response analysis. Wildtype (WT) and 
PINK1 knockout (PINK1 KO) HeLa cells transfected with Parkin were stimulated 
with either a combination of A/O for 3 h or with different concentrations (0.2, 0.8, 
2, 8, 20 µM) of niclosamide (Niclo) for 40 min. Parkin Ser65 phosphorylation 
(pS65Parkin), Parkin, Full length OPA1 (F/L), Cleaved OPA1, ubiquitylated 
CISD1 (CISD1-Ub) and CISD1 were detected by immunoblotting. GAPDH was 
used as a loading control. 
 
Importantly, the ability of niclosamide as well as A/O to induce 
Parkin Ser65 phosphorylation and CISD1 ubiquitylation was 
abolished in PINK1 knockout cells (Figure 1B). However, their 
ability to induce uncoupling was not affected as judged by 
cleavage of OPA1 (Figure 1B). Under similar transfection and cell 
conditions we next undertook a time-course analysis of Parkin 
Ser65 phosphorylation and CISD1 ubiquitylation in the presence 
of 20 μM niclosamide. We observed robust niclosamide induced 
Parkin Ser65 phosphorylation after 20 min of treatment 
(Supplementary Figures 1) associated with ubiquitylation of 
CISD1 (Supplementary Figure 1A). In vitro kinase assays of 
PINK1 in the presence or absence of niclosamide showed no 
evidence for direct activation of PINK1 by the compound (data not 
shown).  
Facile chemical modification of the salicynalide scaffold of 
niclosamide enabled synthesis of three brominated analogues 
known to exert pharmacological efficacy, AM85 (Dibromsalan), 
AM86 (Tribromsalan) and AM87 (Metabromsalan) (Figure 2A) 
(see Supporting Information).
[16]
 To compare the effects of these 
niclosamide analogues on PINK1 activation, HeLa cells were 
treated with 20 µM of niclosamide or AM85-AM87 for 40 min and 
this revealed AM85 to be the most potent analogue as determined 
by Parkin Ser65 phosphorylation and CISD1 ubiquitylation 
(Figure 2B). Interestingly less potent PINK1 activators AM86 and 
AM87 induced similar cleavage of OPA1 to A/O and niclosamide 
indicating broadly similar effects on the ∆ym (Figure 2B). We next 
undertook a dose-response analysis of AM85 on PINK1 activation 
and observed robust Parkin Ser65 phosphorylation and CISD1 
ubiquitylation at 2, 8 and 20 µM but not at lower concentrations 
(Figures 2C). CISD1 ubiquitylation, was also confirmed by pull 
down of ubiquitylated substrates with HALO-UBAUBQLN1 resin 
as previously described (Supplementary Figure 2A).
[4a]
 
Furthermore, time-course analysis of AM85 demonstrated Parkin 
Ser65 phosphorylation and CISD1 ubiquitylation at 40 min but not 
earlier time points that were previously observed for niclosamide 
(Supplementary Figures 2B-C).  
To quantify the degree of mitochondrial uncoupling between 
AM85 and niclosamide, we performed FACS analysis on HeLa 
cells treated with 20 µM of niclosamide and AM85 for 40 min. 
Cells were incubated with CMX ROS, which is a cell permeable 
probe that accumulates in the active mitochondria and emits at 
599 nm.
[17]
 Interestingly, both niclosamide and AM85 promoted 
significant mitochondrial membrane depolarization comparable 
with 3 h A/O-treated cells (Figure 2D and Supplementary Figure 
2d) in agreement with OPA1 cleavage shown above (Figures 1B 
and 2B-C). Critically, the mitochondrial depolarization effect 
induced by both niclosamide and AM85 was reversible since no 
reduction in ROS was detected after compound wash-out (Figure 
2e). FACS analysis also demonstrated no significant toxicity 
under the compound conditions used for niclosamide and AM85 
compared to DMSO (Supplementary Figure 3).  
 
Figure 2. Niclosamide analogue AM85 activate PINK1 in HeLa cells and 
uncouples mitochondria. A. Chemical structures of niclosamide analogues 
AM85, AM86 and AM87. B. Wildtype (WT) HeLa cells transfected with Parkin 
were stimulated with either a combination of A/O for 3 h or 10 µM niclosamide 
(Niclo), AM85, AM86, AM87 for 40 mins. C. WT and PINK1 knockout (PINK1 
KO) HeLa cells transfected with Parkin were stimulated with A/O for 3 h or with 
different concentrations (0.2, 0.8, 2, 8, 20 µM) of AM85 for 40 min. Parkin Ser65 
phosphorylation (pS65Parkin), Parkin, Full length OPA1 (F/L), Cleaved OPA1, 
ubiquitylated CISD1 (CISD1-Ub) and CISD1 were detected by immunoblotting. 
GAPDH was used as a loading control. D. Histograms of CMXRos Fluorescence 
Intensity (arbitrary units, a.u.) for Hela cells treated on site for 3h with A/O, green 
  
 
 
or with 1h of niclosamide (Niclo, red) and AM85 (blue). Values are normalized 
to the vehicle, DMSO (black). E. Quantification of CMXRos Fluorescence 
Intensity (arbitrary units, a.u.) for Hela cells subjected to drug wash out, after 
treatment with A/O (green), niclosamide (Niclo, red), AM85 (blue), normalized 
to the vehicle, DMSO (black). Bars represent the average ratio ± SEM of three 
independent experiments. **p < 0.01, one-way ANOVA followed by Bonferroni 
post-test correction.  
We next determined the ability of niclosamide and AM85 to 
activate PINK1 in cells of pathophysiological relevance to PD. To 
date no studies have assessed PINK1 activity in primary neurons 
under conditions where the PINK1 and Parkin are expressed at 
endogenous levels. Marked neuronal loss and Lewy body 
accumulation occurs in the frontal cortex particularly the anterior 
cingulate gyrus in advancing Parkinson’s disease.
[18]
 Therefore, 
we studied primary cortical neurons derived from E16.5 embryos. 
We initially evaluated Parkin expression in cortical neurons at 
various time points from 3-21 days in vitro (DIV) (Figure 3A). We 
strikingly observed an increase in Parkin expression during 
cortical neuronal growth in vitro that paralleled the expression of 
the pre-synaptic and post-synaptic proteins, synaptophysin and 
PSD95 respectively (Figure 3A).  
 
Figure 3. Niclosamide and analogue AM85 activate PINK1 and uncouple 
mitochondria in primary cortical neurons. A. Detection of Parkin expression 
at different days in vitro (DIV) after plating. PSD95 and synaptophysin were 
used as markers of increasing neuronal complexity. b-actin is used as a loading 
control. B. Time-course analysis of Parkin Ser65 phosphorylation (pS65Parkin) 
and Parkin upon A/O stimulation (10, 20, 40 min, 1, 3, 6 and 9 h) in 12 DIV 
neurons. C. E16.5 derived C57Bl/6J primary cortical neurons after 5, 7, 12, 21 
DIV were stimulated with A/O for 3 h. Parkin Ser65 phosphorylation 
(pS65Parkin) and CISD1 ubiquitylation (CISD1-Ub) were detected. bI-Tubulin 
was used as a loading control. D. 21 DIV C57Bl/6J primary cortical neurons 
were stimulated with either a combination of 10 µM A/O for 3 h or 30 µM 
niclosamide (Niclo) and AM85 for 1 h. Parkin Ser65 phosphorylation 
(pS65Parkin), and Parkin were detected upon A/O stimulation. E. Pull-down of 
ubiquitylated CISD1 (CISD1-Ub) after niclosamide and AM85 treatment of 
PINK1KO WT and HOM 21DIV neurons. MemCode was used as a loading 
control. F. Graph of CMX ROS Fluorescence Intensity (arbitrary units, a.u.) in 
21DIV neurons after treatment with A/O (green), niclosamide (Niclo, red), AM85 
(blue), normalized to the vehicle, DMSO (black). In all graphs, bars represent 
the average ratio ± SEM of two independent experiments. *p < 0.05, **p < 0.01, 
one-way ANOVA followed by Bonferroni post-test correction. G. Niclosamide 
and AM85 treatment induce OPA1 cleavage. Quantification of cleaved OPA1 in 
AM85, niclosamide and A/O treated 21 DIV neurons. Bars represent the 
average ratio ± neurons. Bars represent the average ratio ± SEM of two 
independent experiments and values are ratios between uncleaved and cleaved 
OPA1. **p < 0.01, one-way ANOVA followed by Bonferroni post-test correction. 
At the bottom, exemplary immunoblot of full length (F/L) and cleaved form of 
OPA1. 
 
We next undertook a time-course analysis of 12 DIV neurons 
treated with A/O and observed Parkin Ser65 phosphorylation 
occurring at 10 min of stimulation and becoming maximal by 1 h 
of stimulation and sustained for 9 h (Figure 3B). Furthermore, we 
observed significant CISD1 ubiquitylation in 12 DIV and 21 DIV 
neurons stimulated with A/O for 3 h but not in 5 DIV or 7 DIV 
neurons (Figure 3C). We next tested the ability of niclosamide and 
AM85 to activate PINK1 in 21 DIV neurons. Neurons were treated 
with 30 µM of niclosamide or AM85 for 1 h and this led to 
increased Parkin Ser65 phosphorylation (Figure 3D). Interestingly, 
AM85 exerted a stronger effect on Parkin Ser65 phosphorylation 
than niclosamide and this was also confirmed by CISD1 
ubiquitylation in neurons under similar conditions (Figure 3E). 
This difference was not explained by differences in uncoupling 
since both drugs had a similar effect on mitochondrial 
depolarization as assessed directly by FACS or indirectly by 
cleavage of OPA1 (Figures 3F-G). 
In summary, we report the discovery that the anthelminthic drug, 
niclosamide, and its analogue, AM85, can activate PINK1 in cells. 
Notably, we detected for the first time PINK1-Parkin pathway 
activation in neurons and demonstrated that it can be triggered by 
small molecules. Additionally, we showed that the induction of 
mitochondrial depolarization is capable of activating endogenous 
PINK1 protein in neurons leading to Parkin Ser65 phosphorylation 
and ubiquitylation of its mitochondrial substrate CISD1. The 
mechanism of action of niclosamide and AM85 appears to be 
indirect and mediated by their mitochondrial uncoupling 
properties although this is not sufficient to explain the greater 
potency of AM85 in neurons. Niclosamide has been used safely 
in humans for over half a century to treat helminth infections and 
is currently being tested in multiple clinical trials in a variety of 
human cancers, as well as rheumatoid arthritis.
[19]
 Our data 
suggests that niclosamide and/or its analogues could have 
therapeutic benefit in slowing down Parkinson’s disease 
progression through the activation of PINK1. Further in vivo 
studies in appropriate PD models are warranted to test this 
hypothesis. 
  
 
 
Experimental Section 
Immunoblotting and immunoprecipitation 
Tissues, primary cortical neurons or Hela cells were sonicated in lysis 
buffer containing 50 mM Tris–HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 1% 
(w/v) Triton, 1 mM sodium orthovanadate, 10 mM sodium 
glycerophosphate, 50 mM sodium fluoride, 10 mM sodium pyrophosphate, 
0.25 M sucrose, 1 mM benzamidine, 0.1 mM PMSF and protease inhibitor 
cocktail (Roche). Following the sonication, lysates were incubated for 30 
min on ice. Samples were spun at 20,800 x g in an Eppendorf 5417R 
centrifuge for 30 min. Supernatants were collected and protein 
concentration was determined using the Bradford kit (Pierce). Samples 
were subjected to SDS/PAGE (4–12% gels) and were transferred on to 
Protran 0.2 NC nitrocellulose membranes (Amersham). Membranes were 
blocked for 1 h at room temperature with 5% nonfat milk or bovine serum 
albumin (BSA) in TBST [Tris-buffered saline (50 mM Tris/HCl and 150 mM 
NaCl, pH 7.5) containing 0.1% Tween-20 in phosphate buffered saline 
(PBS) pH 7.4 and probed with the indicated antibodies overnight at 4 °C. 
Detection was performed using HRP-conjugated secondary antibodies 
and enhanced chemiluminescence reagent. 
Ubiquitin enrichment  
For ubiquitylated protein capture, 400 μg of extract was used for pull down 
with HALO‐UBAUBQLN1 resin as described previously5. Halo-tagged 
UBDs were incubated with 200 μl of the HaloLink resin (Promega) in 
binding buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.05% NP-40) 
overnight at 4 °C. 20 μl of Halo Tube beads were added to neuronal or 
tissue lysates and were incubated for 4 h at 4 °C. The beads were washed 
three times with lysis buffer containing 0.25 M NaCl and eluted by 
resuspending in 20 μl of 1× LDS sample buffer with 1mM DTT. 
Flow Cytometry Analysis of mitochondrial membrane potential  
Hela Cells were incubated with 20 μM niclosamide (manufacturer), AM85 
(manufacturer) for 40 min before trypsinization and collection. 
Oligomycin(manufacturer) and Antimycin (manufacturer) 20 μM were used 
as positive control and incubated for 3 h before samples harvest. DMSO 
(Sigma Aldrich) at the same concentration was used as control. After 10 
min from start of drug   treatment, cells were treated with 100 nM Mito 
Tracker CMXRos (Cell Signaling Technology) for 30 min directly on wells. 
Drug Washout was performed incubating trypsinized floating cells with 100 
nM Mito Tracker CMXRos (Cell Signaling Technology) for 30 min at 37 °C 
in drug absence. All harvested cells were incubated for 5 min on ice after 
CMXRos incubation and then centrifuged and washed two times with a 1% 
BSA/PBS solution. Finally, cells were treated with DAPI (1:200) solution (1 
mg/ml DAPI, 50 μg/mL RNaseA in 1% BSA/PBS) and transferred to FACS 
tubes for analysis. Samples were acquired using a BD FACS Canto and 
the results analysed using FlowJo software. 
Statistical analysis 
Statistical analysis of groups with normal distributions was performed 
using One-way ANOVA or two-way ANOVA followed by Holm-Sidak or 
Bonferroni post-test. Differences among groups were considered 
statistically significant when p < 0.05. Data throughout the text are reported 
as average values ± SEM unless otherwise specified. 
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I. Antibodies and reagents 
The following primary antibodies were used: mouse monoclonal antibodies against Parkin (Santa Cruz), 
βI-tubulin (Sigma), β-actin (Sigma), GAPDH (Santa Cruz), PSD95 (Cell Signaling), synaptophysin (cell 
signalling), CISD1 (Proteintech). Horseradish-peroxidase (HRP)-conjugated secondary antibodies 
(Sigma) were used. Anti-Parkin phospho-Ser65 rabbit monoclonal antibody was raised by Epitomics in 
collaboration with the Michael J Fox Foundation for Research. 
Stock solutions of niclosamide (Sigma), Antimycin A (Sigma) Oligomycin A (Sigma) were used for 
experiments in vitro. Unless otherwise specified, general reagents and chemicals were from Sigma and 
cell culture reagents were from Invitrogen. 
 
  
 
 
 
II. Cell culture 
HeLa cells stably expressing untagged Parkin WT and PINK 1 KO, were cultured using DMEM 
(Dulbecco’s modified Eagle’s medium) supplemented with 10% FBS, 2 mM L-glutamine, 
1×penicillin/streptomycin. To uncouple mitochondria, cells were treated with 10 µM Antimycin (Sigma) 
and 1 µM Oligomycin dissolved in DMSO for 3 h. To express Parkin, cell transfections were performed 
using polyethylenimine (Polysciences) according to the manufacturer's instruction. 
Primary cortical neurons were isolated from the brain of WT embryos of either sex at E16.5. Embryonic 
cortices were collected in HBSS, and cells were dissociated by incubation with trypsin (GIBCO) at 37°C. 
Cells were then diluted in Neurobasal medium containing B27 supplement, Glutamax, 
penicillin/streptomycin and plated at a density of 6.0 × 106 cells/well on 6-well plates coated with 0.1 
mg/ml poly-L-lysine (PLL; Sigma). Neurons were cultured at 37 °C in a humidified incubator with 5% 
CO2. Every 7 days, the medium was replaced with fresh medium containing B27. Neurons were treated 
with 30 µM niclosamide and analogues for 1h at 37 °C. 
 
III. Synthesis of AM85-AM87 compounds 
To a stirring solution of the relevant salicylic acid (1 eq.) in dry THF, PyBop (1.2 eq.) and triethylamine 
(3 eq.) were added. After 10 min, the relevant aniline (1.5 eq.) was added to the cloudy white suspension 
and stirred at room temperature for 12 h. The reaction mixture was then concentrated under reduced 
pressure to afford a yellow oil, which was subsequently dissolved in water and extracted in ethyl acetate. 
The combined organic layers were dried (MgSO4), filtered and concentrated under reduced pressure to 
form a viscous orange oil. Flash column chromatography employing ethyl acetate:hexane (1:1) was used 
to yield the desired AM compounds as off-white solids. 
5-Bromo-N-(4-bromophenyl)-2-hydroxybenzamide (AM85). Yield 10%. 
1
H NMR (500 MHz, DMSO): δ 
11.73 (s, 1H, OH), 10.49 (s, 1H, NH), 8.03 (d, J = 2.5 Hz, 1H), 7.69 (d, J = 8.9 Hz, 2H), 7.57 (m, 3H), 
6.97 (d, J = 8.8 Hz, 1H). 
13
C NMR (126 MHz, DMSO): δ 165.36, 157.53, 137.98, 136.31, 132.39, 131.77, 
123.10, 120.92, 119.97, 116.46, 110.59. HRMS m/z [M+H]
+
 calcd. for C13H10NO2Br2: 369.9078, found: 
369.9067. Anal. Calcd for C13H9NO2Br2: C, 42.08; H, 2.44; N, 3.77. Found: C, 41.93; H, 2.61; N, 3.93.  
3,5-Dibromo-N-(4-bromophenyl)-2-hydroxybenzamide (AM86). Yield 9%. 
1
H NMR (500 MHz, DMSO): 
δ 12.75 (s, 1H, OH), 10.71 (s, 1H, NH), 8.26 (s, 1H), 8.01 (s, 1H), 7.67 (d, J = 8.6 Hz, 2H), 7.59 (d, J = 
8.5 Hz, 2H). 
13
C NMR (126 MHz, DMSO): δ 167.09, 156.71, 139.09, 137.27, 132.07, 130.26, 124.06, 
119.10, 117.41, 112.93, 110.39. HRMS m/z [M+H]
+
 calcd. for C13H9NO2Br3: 447.8183, found: 447.8184. 
HPLC (8 min), tR = 5.21 min, purity: 97%.  
3,5-Dibromo-2-hydroxy-N-phenylbenzamide (AM87). Yield 15%. 
1
H NMR (500 MHz, DMSO): δ 13.01 
(s, 1H, OH), 10.65 (s, 1H, NH), 8.31 (d, J = 2.2 Hz, 1H), 8.02 (d, J = 2.2 Hz, 1H), 7.68 (d, J = 7.7 Hz, 
2H), 7.41 (t, J = 7.9 Hz, 2H), 7.21 (t, J = 7.4 Hz, 1H). 
13
C NMR (126 MHz, DMSO): δ 167.18, 156.98, 
138.91, 137.87, 130.26, 129.21, 125.40, 122.23, 118.88, 113.14, 109.71. HRMS m/z [M+H]
+
 calcd. for 
C13H10NO2Br2: 369.9078, found: 369.9087. Anal. Calcd for C13H9NO2Br2: C, 42.08; H, 2.44; N, 3.77. 
Found: C, 41.91; H, 2.37; N, 3.71. 
 
 
 
 
 
 
 
 
 
  
 
 
IV. Supplementary figure 1 
 
 
Supplementary 1. Niclosamide activates PINK1 after 20 minutes treatment.  A) Niclosamide-
induced Parkin activation is PINK1 dependent and can be detected after 20 min of in vitro stimulation. 
HeLa cells transfected with Parkin were stimulated with either a combination of antimycin A and 
oligomycin A (A/O) for 3 h or with 10 µM of niclosamide (Niclo) for 5, 10, 20, 40 min. Detection of 
Parkin S65 phosphorylation (pS65Parkin), Parkin, Full length (F/L) and cleaved OPA1, CISD1 
ubiquitylation (CISD1-Ub) can be detected in niclosamide stimulated HeLa cells at different time points. 
GAPDH and HSP60 were used as loading controls.  B) Quantitative analysis of Parkin S65 
phosphorylation after niclosamide treatment at different time points (5, 10, 20, 40 min). Bars represent 
the average ratio ± SEM of two independent experiments and the value is a ratio between pS65 Parkin 
and total Parkin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
V. Supplementary figure 2 
 
Supplementary 2. AM85 activates PINK1 and uncouples mitochondria after 40 minutes of 
treatment. A) CISD1 ubiquitylation after niclosamide and AM85 treatment is PINK1 dependent. 
Wildtype (WT) and PINK1 knockout (Pink1 KO) HeLa cells transfected with Parkin were stimulated 
with a combination of 10 µM antimycin A and 1 µM oligomycin A (A/O) for 3 h, 10 µM niclosamide 
(Niclo) and 10 µM AM85 for 40 min. CISD1 ubiquitylation (CISD1-Ub) was detected by western 
blotting. B) Time course of AM85 in HeLa cells. Detection of Parkin S65 phosphorylation (pS65 Parkin), 
Parkin, Full length and cleaved OPA1 and CISD1 ubiquitylation (CISD1-Ub) upon different time points 
of AM85 treatment (5, 10, 20, 40 min). C) Quantitative analysis of Serine 65 phosphorylation in response 
to AM85 treatment at different time points. Bars represent the average ratio ± SEM of 2 independent 
experiments and the value is a ratio between pSer65 Parkin and total Parkin. D) Niclosamide and AM85 
uncouple mitochondria in HeLa cells. Exemplary FACS graph of CMXRos fluorescence intensity in Hela 
cells treated on site. Hela cells were treated on site with antimycin A and oligomycin A (A/O, green), 
niclosamide (Niclo, red), AM85 (blue) and the vehicle, DMSO (black). 
 
 
  
 
 
 
 
VI. Supplementary figure 3 
 
Supplementary 3. Mitochondrial membrane potential is restored upon wash out of AM85 and 
niclosamide. A) Exemplary FACS curve of CMXRos fluorescence intensity in Hela cells subjected to 30 
min washout treatment. Hela cells treated with Antimycin A/ Oligomycin A (A/O, green curve), 
niclosamide (Niclo, red curve), AM85 (blue curve), normalized to the vehicle, DMSO (black curve). B) 
Niclosamide and AM85 do not induce cell death. Percentage of alive (bottom percentage) and dead cells 
(upper percentage) after niclosamide (bottom left square) and AM85 (bottom right square) treatment 
compared to DMSO (upper left square) and A/O (upper right square) treated cells. FSC-A (forward scatter 
area). 
 
 
 
 
